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Role of Tea Polyphenols in 
Metabolic Syndrome
Telma Angelina Faraldo Corrêa, 
Adriana Campos Rozenbaum and Marcelo Macedo Rogero
Abstract
Metabolic syndrome (MetS) increases the risk of type 2 diabetes and cardio-
vascular diseases (CVD). Tea (Camellia sinensis), one of the most consumed bev-
erages in the world, is rich in polyphenols, mainly catechins. Tea polyphenols may 
ameliorate obesity by reducing body weight, increasing energy expenditure and 
fat oxidation, stimulating lipolysis, and improving thermogenesis. Tea polyphe-
nols also reduce the risks of type 2 diabetes (T2D), hypertension, hyperlipidemia, 
and inflammation. Results of clinical trials on the effects of the consumption of 
tea beverage, tea extracts, or isolated tea polyphenols on biomarkers of metabolic 
syndrome will be reviewed in this study. The effects of tea polyphenols on antioxi-
dant status and low-grade chronic inflammation and the molecular mechanisms 
involved will also be discussed.
Keywords: Camellia sinensis, catechins, inflammation, insulin resistance, 
dyslipidemia, hypertension, obesity
1. Introduction
Metabolic syndrome (MetS) is a cluster of interrelated prejudicial conditions 
that leads to type 2 diabetes (T2D) and cardiovascular disease (CVD). These condi-
tions include elevated fasting plasma glucose level (hyperglycemia), abdominal/
visceral obesity, dyslipidemia, and hypertension [1, 2]. The International Diabetes 
Federation (IDF) estimates that around 20–25% of the global adult population 
suffer from MetS and are more likely to die from a heart attack or stroke compared 
with people without MetS [1].
Since there is no specific treatment for MetS, individual characteristics must 
be taken into consideration. There is a need for long-term studies to determine 
whether existing and new therapeutic agents benefit patients with MetS, reducing 
the effects of MetS and preventing the appearance of associated diseases and to 
evaluate the potential of novel candidates as effective treatment options [3]. Several 
clinical studies demonstrate that lifestyle modification, especially dietary changes, 
is an effective strategy to reduce several factors responsible for the development of 
MetS. Introducing foods rich in dietary phytochemicals, such as polyphenols, into 
the diet of an individual is an effective lifestyle modification for the prevention of 
several diseases, including MetS [4, 5].
Polyphenols (phenolic compounds), one of the most relevant families of 
phytochemicals with health benefits, are biomolecules found in natural products. 
Several preclinical studies report that some polyphenols exert protective effects in 
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many diseases, including CVD and MetS, both triggered by oxidative stress [6, 7]. 
These compounds present antioxidant and anti-inflammatory properties and may 
be able to delay or prevent MetS by decreasing blood pressure, blood glucose levels, 
and body weight, as well as by improving lipid metabolism [7, 8]. One of the main 
sources of polyphenols is tea prepared from the processed leaves of Camellia sinensis, 
an herbal plant belonging to the Theaceae family. The chemical composition of tea is 
characterized by the presence of polyphenols (especially catechins), phenolic acids, 
amino acids, proteins, and fats. The catechins most commonly found in tea include 
epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate 
(ECG), and epicatechin (EC) (Figure 1). These compounds constitute up to 30% of 
the dry leaf weight. A typical green tea beverage, with 2.5 g of tea leaves and 250 mL 
of hot water, contains 240–320 mg catechins and 60–65% EGCG [7, 9, 10]. Although 
the bioavailability of tea polyphenols is not clearly known, it depends on the 
molecular size and the number of phenolic groups. A review demonstrated that the 
consumption of 2 or 3 cups of tea daily resulted in 0.2–0.3 μM peak plasma levels of 
tea catechins [9, 11]. Notably, the health-promoting properties of green tea are due to 
the presence of the catechins mentioned earlier, mainly because of their antioxidant 
(scavenging of reactive oxygen species, inhibition of the formation of free radicals, 
and lipid peroxidation) and anti-inflammatory effects [10].
2. Tea, obesity, and inflammation
Obesity is a major health concern in the developed and developing world. 
Obesity leads to an inflammatory condition that is directly involved in the etiol-
ogy of CVD, T2D, and certain types of cancer. Furthermore, the accumulation of 
adipose tissue in the abdominal region is a significant risk factor for the develop-
ment of MetS and associated morbidities. It should be noted that inflammation is 
Figure 1. 
Chemical structure of green tea catechins: epicatechin (A), epigallocatechin (B), epicatechin-3-gallate (C), 
epigallocatechin-3-gallate (D).
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a common feature implicated in the pathophysiology of many obesity-associated 
disorders. The inflammatory response in obese and MetS individuals manifests 
systemically and is characterized by a chronic low-intensity reaction, unlike classi-
cal inflammation [12–16].
The anti-inflammatory and anti-obesity effects of Camellia sinensis have been 
associated with its catechin content, and EGCG is the most abundant and pharmaco-
logically active catechin. Green tea, which is more effective than black tea, has been 
shown to significantly alleviate MetS symptoms, such as abdominal adiposity indicated 
by waist circumference in obese subjects. The anti-obesity mechanisms of tea polyphe-
nols are associated with two major mechanisms: (i) decreasing the absorption of lipids 
and proteins in the intestine by tea constituents, thus reducing calorie intake, and (ii) 
activating adenosine monophosphate-activated protein kinase (AMPK) by tea polyphe-
nols that are bioavailable in the liver, skeletal muscle, and adipose tissues. The relative 
importance of these two mechanisms depends on the types of tea and diet consumed by 
individuals. It should be noted that AMPK activation can reduce gluconeogenesis and 
fatty acid synthesis, leading to bodyweight reduction and MetS alleviation [17, 18].
Clinical trials [19–21] verified that green tea reduced body weight and other 
biomarkers linked to MetS (Table 1).
Cellular, animal, and human experiments demonstrated that green tea and 
its major component, EGCG, have anti-inflammatory effects. Moreover, EGCG 
Participants Study type Intervention Outcomes Ref.
35 subjects with 
obesity and 
MetS
Randomized, 
controlled 
prospective trial
Green tea (4 cups/day), 
green tea extract  
(2 capsules and 4 
cups of water/day), or 
placebo for 8 weeks
Both interventions 
↓ body weight and 
BMI. Green tea 
beverage also ↓ lipid 
peroxidation
[19]
70 moderately 
overweight 
subjects
Intervention Green tea extract  
(4 capsules/day—
375 mg of catechins) 
for 12 weeks
↓ Body weight [20]
23 overweight 
subjects
Double-blind 
study
Green tea beverage 
containing 588 mg or 
126 mg catechins for 
12 weeks
↓ Body fat 
parameters
[21]
56 obese, 
hypertensive 
subjects
Double-blind, 
placebo-
controlled trial
1 capsule (379 mg 
green tea extract) or 
placebo for 3 months
↓ TNF-α and CRP 
serum levels
↑ antioxidant status 
and HDL-C
↓ TC, LDL-C, and 
TG
[22]
1.704 
overweight or 
obese subjects
Meta-analysis Green tea/green tea 
extract (126–800 mg 
catechins) for 
12–24 weeks
↓ LDL-C and TC [23]
1356 subjects Meta-analysis EGCG (107 to 857 mg/
day—2 to 8 cups of 
green tea per day) for 4 
to 14 weeks
↓ LDL-C [24]
BMI, body mass index; CRP, C-reactive protein; EGCG, epigallocatechin gallate; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; TC, total cholesterol; TG, 
triglycerides; TNF-α, tumor necrosis factor-alpha; ↑, Increase; ↓, reduction.
Table 1. 
Clinical trials showing the effects of tea or tea catechins on inflammation, obesity, and lipid profile.
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inhibits the in vitro activation of the transcription factor NF-κB and attenuates the 
IκB-α degradation induced by tumor necrosis factor-alpha (TNF-α) activation. The 
anti-inflammatory mechanism of EGCG seems to be associated with a decrease in 
the activity of the IKK-β protein, involved in the phosphorylation of IκB-α. Because 
of this effect on the NF-κB signaling pathway, catechins can reduce the gene expres-
sion of COX-2. In addition, EGCG demonstrates anti-inflammatory activities in the 
MAPK pathway by inhibiting the phosphorylation of p38. Catechins also reduce 
the gene expression of c-Jun N-terminal kinase (JNK) protein and the transcription 
factor AP-1 [25, 26].
It should be noted that only a limited number of studies on humans provided 
strong evidence related to the anti-inflammatory activity of green tea. One example 
is a double-blind, placebo-controlled trial, in which 56 obese, hypertensive subjects 
received green tea extract or placebo for 3 months [22]. Green tea extract reduced 
diabetes and inflammation risk, increased total antioxidant status, and improved 
the lipid profile.
3. Tea and lipid profile
Hyperlipidemia, characterized by increased levels of total cholesterol (TC) and 
low-density lipoprotein (LDL-C), is a major risk factor for CVD. Several clinical tri-
als demonstrated that the ingestion of polyphenols such as flavonoids and phenolic 
acids can improve the concentrations of TC, LDL-C, and high-density lipoprotein 
(HDL-C) [8].
Green tea beverage consumption and green tea extract supplementation can 
also improve lipid profile, reducing blood TC and LDL-C concentrations, especially 
when used for a long time. These changes are due to the presence of major tea 
polyphenols, namely, the catechins [27, 28]. A study conducted on rats fed with 
atherogenic diet demonstrated that the supplementation with green tea prepara-
tion consisting of 66.5% EGCG and other catechins could decrease plasma TC and 
LDL-C levels and increase plasma HDL-C levels [29]. Another study on rats and 
atherogenic diet indicated that EGCG can significantly reduce TC, LDL-C, very 
low-density lipoprotein cholesterol (VLDL-C), triacylglycerols (TG), and cardiac 
risk ratio values while increasing the concentration of HDL-C [30].
Studies on humans also reported that EGCG can improve lipid profile. Its 
mechanisms may be associated with decreasing the absorption of lipids, inhibiting 
the lipogenesis pathway, and attenuating inflammation [23, 24, 31] (Table 1).
Other green tea catechins may have a beneficial effect on plasma TC and LDL-C 
levels in humans. Kim et al. [32] reviewed 20 trials and verified that the intake of 
green tea catechins, at doses of 145 to 3.000 mg per day, reduced TC by 5.5 mg/dL 
and LDL-C by 5.3 mg/dL, while there were no changes in plasma HDL-C levels.
More importantly, green tea can decrease plasma TC and LDL-C levels in 
overweight or obese people with no side effects, especially with long-term 
consumption [23].
Consumption of green tea extract catechin complex (843 mg of EGCG, 202 mg 
of ECG, 107 mg of EGC, and 107 mg of EC), for 12 months, significantly reduced 
(compared with the placebo group) plasma TC, LDL-C, and non-HDL-C levels in 
postmenopausal women. In hypercholesterolemic participants, green tea extract 
supplementation resulted in a reduction of 8.5% in TC and 12.4% in LDL-C con-
centrations. This study suggests that green tea extract, with high concentrations of 
catechins, may be recommended for lowering cholesterol, especially in those with 
high cholesterol concentrations [33].
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4. Tea and blood pressure
Hypertension is a multifactorial clinical condition characterized by constant 
elevation of systolic blood pressure (SBP) levels ≥140 and/or diastolic blood 
pressure (DBP) ≥ 90 mmHg. It is often associated with metabolic disorders and 
functional and/or structural changes in target organs, aggravated by the presence 
of other risk factors, such as dyslipidemia, abdominal obesity, glucose intoler-
ance, and T2D [34]. Hypertension is one of the leading risk factors for CVD, and 
it is a major cause of premature death worldwide; it affects about 1 billion people 
worldwide [34].
Tea flavonoids can reduce the risk of hypertension and consequently the risk of 
CVD [9, 35]. Catechins act as antioxidants and vasodilators and inhibit endothelial 
dysfunction and thrombogenesis [9, 36]. Catechins might reduce blood pressure by 
enhancing nitric oxide signaling [9]. The health benefits of tea for blood pressure 
were demonstrated in healthy subjects, diabetic subjects, and obese and/or hyper-
tensive subjects [37]. Clinical trials showing the effect of tea on blood pressure are 
summarized in Table 2. It should be noted that several factors may influence the 
effect of tea consumption on blood pressure such as the duration and frequency of 
consumption, dosage, tea bioactive compounds, the evaluated population, and the 
degree of hypertension [37].
4.1 Molecular mechanisms of tea regulating blood pressure
Evidence indicates that vascular superoxide anion inactivates nitric oxide (NO) 
and plays a critical role in the development of hypertension. NO reacts with super-
oxide anion to form peroxynitrite. Peroxynitrite can cause protein tyrosine nitra-
tion, which modifies protein structure and function and affects cell homeostasis, 
oxidizes LDL-C, and leads to reduced activity of endothelial nitric oxide synthase 
(eNOS) [44, 45]. Angiotensin II generates vascular superoxide anion by activat-
ing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Superoxide 
anion contributes to increased blood pressure, endothelial dysfunction, vascular 
remodeling, and sodium retention, consequently contributing to the develop-
ment of hypertension (Figure 2). Possibly, green tea extract reduces the risk of 
hypertension by reducing vascular reactive oxygen species (ROS) formation and 
NADPH oxidase activity [37]. In rats, decaffeinated green tea extract stimulated 
the activation of the eNOS via the phosphatidylinositol 3-kinase (PI3-kinase)/Akt 
pathway [46].
Caveolin-1, the major negative regulator of eNOS activity, has its gene expres-
sion attenuated by green tea polyphenols via the activation of extracellular 
signal-regulated kinase 1/extracellular signal-regulated kinase 2 (ERK1/ERK2) 
and inhibition of p38 mitogen-activated protein kinase (MAPK) signaling path-
ways [47].
Another mechanism by which tea consumption can reduce the risk of hyperten-
sion is by inhibiting renin activity. The study conducted by Li et al. [48] showed 
that oolong and black tea extracts inhibited renin activity. The beneficial effect was 
attributed to thearubigins. However, monomeric catechins did not contribute to the 
inhibitory effect promoted by the tea extracts.
Endothelin-1 may contribute to hypertension by enhancing vascular superoxide 
anion production via ETA/NADPH oxidase. Evidence indicates that epigallocat-
echin gallate reduces endothelin-1 expression and secretion from endothelial cells, 
partly via Akt- and AMPK-stimulated forkhead box transcription factor class O1 
(FOXO1) regulation of the endothelin-1 promoter [37].
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Participants Study type Intervention Outcomes Ref.
4579 older Chinese 
(>60 years) 
without 
hypertension or 
antihypertensive 
treatment
Cross-
sectional
Green tea (~90% 
of subjects) 
nonhabitual 
drinkers, l–5x/
week; ≥6x/week
Reduction of 16 and 22% 
with tea consumption 
1–5 times per week and 
≥6 times per week, 
respectively
[36]
20 subjects with 
T2D (mean 
53 years old; BMI, 
30 kg/m2)
Parallel, 
double-blind, 
placebo-
controlled
Decaffeinated 
green tea extract 
(400 mg/ day) 
or placebo for 
12 weeks
No difference in 
blood pressure, 
anthropometric, and 
metabolic parameters 
when compared to 
placebo
[38]
100 mildly 
hypertensive 
patients with 
diabetes
Randomized 
clinical trial
3 g/150 mL 
of sour tea or 
3 g/150 mL of 
green tea (3x/day) 
for 4 weeks
↓ Systolic and diastolic 
blood pressure in both 
groups
[39]
56 obese, 
hypertensive 
subjects
Double-
blind, 
placebo-
controlled 
trial
1 capsule (379 mg 
green tea extract) 
or placebo for 
3 months
↓ Systolic and diastolic 
blood pressure compared 
with placebo
[22]
19 hypertensive 
subjects
Randomized, 
double-blind, 
controlled, 
cross-over 
study
Black tea (129 mg 
flavonoids) or 
placebo (2x/day) 
for 8 days
↓ Systolic (3.2 mmHg) 
and diastolic 
(2.6 mmHg) blood 
pressure and prevented 
blood pressure increase 
after a fat load
[40]
123 prediabetic 
subjects
Randomized 
controlled 
clinical trial
600 mL/day 
of green tea or 
control (warm 
water) for 
14 weeks
↓ Mean arterial pressure
↓ Waist/hip ratio 
compared to control
Did not affect fasting 
plasma glucose nor 
HbA1C level
[41]
1697 subjects 
(22–74 years)
Meta-analysis Green tea (208 
to 1344 mg/day 
of catechin) for 
3–16 weeks
↓ Systolic (1.17 mmHg) 
and diastolic 
(1.24 mmHg) blood 
pressure, no effect of 
caffeine, effect of low 
catechin dose was greater 
than high catechin
[42]
971 overweight 
or obese subjects 
(29–54 years)
Meta-analysis Green tea/
reen tea extract 
(320–1207 mg 
of catechin) for 
3–16 weeks
↓ Systolic and diastolic 
blood pressure in 
normotensive and 
hypertensive subjects. 
Significant reduction 
only for low catechin 
dose (250 mg of EGCG/
day) and intervention 
≥3 months
Caffeine did not 
interfere with the results
[43]
BMI, body mass index; EGCG, epigallocatechin gallate; HbA1C, glycated hemoglobin A1C; T2D, type 2 diabetes; ↓, 
reduction.
Table 2. 
Clinical trials showing the tea effect on blood pressure.
7Role of Tea Polyphenols in Metabolic Syndrome
DOI: http://dx.doi.org/10.5772/intechopen.92888
5. Tea and insulin resistance/diabetes
Insulin resistance is a key feature of MetS and an important risk factor for 
CVD and T2D. Diabetes is a global health issue with high morbidity and mortal-
ity. The global prevalence of diabetes was 8.5% in 2014. In 2016, about 3.7 million 
deaths were caused by high blood glucose levels and diabetes. Almost half of 
the deaths caused by high blood glucose levels occur before the age of 70. T2D is 
linked to insulin resistance, altered lipid profile, hypertension, and endothelial 
dysfunction [49].
Recent evidence indicates that tea consumption improves insulin sensitivity and 
reduces the risk of T2D [9, 50]. Possibly, tea polyphenols act on gut microbiota, 
increase the probiotic species in the intestine, and attenuate the gene expression 
of enzymes involved in gluconeogenesis (phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase) and glucose production in the liver, mediated 
by AMPK activation [9].
In vitro, in vivo, and clinical studies have shown that green tea catechins, mainly 
EGCG, have various antidiabetic activities [50–53]. However, some studies have 
shown that there are no beneficial effects of tea on T2D [51, 52, 54, 55] (Table 3).
5.1 Molecular mechanisms of tea regulating insulin resistance/T2D
Green tea enhances glucose-stimulated insulin secretion through the cyclic 
adenosine monophosphate (cAMP)/Akt pathway. Moreover, EGCG could activate 
Figure 2. 
In hypertension, there is excessive ROS generation in endothelial cells induced by angiotensin II. ROS excess 
can stimulate the NF-kB pathway and increase endothelial inflammation. ROS excess may also increase 
LDL-C oxidation and inhibit prostacyclin; superoxide anion reacts with NO to form peroxynitrite, which is 
cytotoxic. The NO loss may reduce vasorelaxation and contribute to endothelial dysfunction and hypertension. 
Green tea extract may inhibit the ROS production as well as Oolong tea and black tea may inhibit renin, and 
consequently angiotensin II. Ang II: angiotensin II; AT1R: angiotensin II type 1 receptor; ICAM-1: intercellular 
adhesion molecule 1; LDL-ox: oxidized LDL-C; NF-kB: nuclear factor kappa B; NO: nitric oxide; ROS: 
reactive oxygen species; VCAM-1: vascular cell adhesion molecule 1. →: stimulation; ⊥: inhibition.
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Participants Study design Outcome Ref.
13 normal subjects and 
11 prediabetic subjects
Randomized, 
double-blind, placebo-
controlled crossover 
study
Placebo, low dose of 
black tea polyphenol 
(110 g) or high dose 
(220 g) of polyphenol + 
sucrose (50 g)
Samples collected at 0, 
30, 60, 90, and 120 min 
from tea intake
Low dose and high dose of 
polyphenol reduced incremental 
blood glucose area under the curve 
(AUC) compared with placebo 
in both normal and prediabetic 
subjects. No significant difference 
between low dose and high dose of 
polyphenol
[56]
92 subjects with T2D 
and lipid abnormalities
Double-blinded, 
randomized and 
placebo-controlled 
clinical trial
500 mg green tea 
extract (3x/day) or 
control (cellulose) for 
16 weeks
↓ Triacylglycerols
↓ HOMA-IR
↑ HDL-C
↑ GLP-1
[57]
49 subjects with 
T2D (average age 
of 65 years; median 
duration of diabetes, 
6 years) 80% of them 
using hypoglycemic 
medication
A double-blind, 
placebo-controlled, 
randomized trial 
Placebo, 375 mg 
or 750 mg/day for 
3 months
Extract of green and black tea did 
not show a hypoglycemic effect
[54]
Overweight or 
obese male subjects 
(40–65 years)
Placebo-controlled, 
randomized trial 
400 mg capsules of 
EGCG or placebo 
(lactose)—2x/day for 
8 weeks
No effect on insulin sensitivity, 
insulin secretion, or glucose 
tolerance
[55]
1584 subjects Meta-analysis
Green tea catechins 
with or without caffeine 
≥12 weeks <12 weeks
↓ Fasting blood glucose
Glucose-lowering effect was 
observed when follow-up 
≥12 weeks
[58]
30 subjects with T2D Randomized controlled 
trial 600 mL/day of 
black tea or 200 mL/day 
of black tea for 12 weeks
↓ HbA1C with 600 mL/day
↓ Pro-inflammatory CD3+ CD4+ 
IL-17+ cells
[59]
56 obese, hypertensive 
subjects
Double-blind, placebo-
controlled clinical trial 
1 capsule/day (379 mg 
of green tea extract) or 
placebo for 3 months
↓ Systolic and diastolic blood 
pressure
↓ Fasting serum glucose
↓ Insulin resistance (HOMA-IR)
↓ TNF-α and CRP
↓ Total antioxidant status
↓ Total cholesterol, LDL-C, and 
triacylglycerols
↑ HDL-C
[22]
68 overweight subjects 
with T2D (20–65 years)
Randomized, 
double-blind, placebo-
controlled clinical trial
1500 mg of 
decaffeinated green tea 
extract/day or placebo 
(cellulose) for 16 weeks
↓ HbA1C, ↓ HOMA-IR, ↑ ghrelin, ↓ 
waist circumference
[60]
9Role of Tea Polyphenols in Metabolic Syndrome
DOI: http://dx.doi.org/10.5772/intechopen.92888
AMPK to improve the shutdown of the insulin stress signal pathway caused by 
serine phosphorylation of insulin receptor substrate-1 (IRS-1), improving insulin 
resistance [50]. High plasma glucose level increases ROS production, while EGCG 
improved insulin resistance by scavenging ROS. ROS plays a key role in increasing 
JNK and IRS-1 serine phosphorylation and reducing the transduction of insulin 
signal [62]. Green tea catechin increases insulin sensitivity by directly activating 
peroxisome proliferator-activated receptor (PPAR) γ [50]. In addition to insulin 
sensitivity, EGCG can also inhibit glucose absorption by competitively binding with 
the sodium-glucose transporter-1 (SGLT-1) in intestinal epithelial cells and enhance 
glucose uptake in muscles and adipocytes via enhancement of the GLUT4 expres-
sion [44, 53].
Most studies showing the beneficial effects of EGCG on glucose homeostasis 
were performed in vitro. EGCG showed an insulin-like activity through the 
reduction of gluconeogenic enzymes (glucose-6-phosphatase and PEPCK) in 
hepatocytes by suppressing their gene expression [51, 52]. In myocytes, green tea 
or EGCG stimulates GLUT4 translocation and glucose uptake via the PI3-kinase/
Akt signaling pathway; alternatively, muscle glucose uptake occurs via AMPK [52]. 
In laboratory animals, EGCG improved insulin sensitivity in peripheral organs 
and inhibited gluconeogenesis [51]. In humans, EGCG can protect pancreatic β 
cell from cytokines, inhibiting the NF-kB activation [63]. Tea also reduces carbo-
hydrate absorption by inhibiting α-amylase, β-glucosidase, and sodium-glucose 
transporters [51, 56].
Black tea rich in theaflavins decreases the risk of T2D by inhibiting obesity 
through AMPK phosphorylation and promoting the browning of white adipose 
tissue [50]. The pro-inflammatory cytokines TNF-α and interleukin (IL)-1 are 
involved in obesity-associated insulin resistance and T2D. Black tea consumption 
has a potential role in downregulating serum TNF-α and IL-1 levels and upregulat-
ing IL-10, an anti-inflammatory cytokine [63].
6. Conclusion
Tea contains polyphenols that may provide an important source of dietary 
antioxidants in humans. Moderate consumption of tea seems to reduce the risk of 
MetS and/or MetS-related diseases. EGCG, the main catechin in tea, presents major 
health benefits. Green tea seems to have the best potential antioxidant effects when 
compared to other teas. It is worth mentioning that most of the studies have not 
demonstrated toxicity due to tea consumption or supplementation; however, fur-
ther research, especially in humans, should be conducted to confirm this property 
and evaluate the underlying mechanisms of action.
Participants Study design Outcome Ref.
66 subjects with T2D 
(32–73 years)
Randomized controlled 
trial Green tea extract 
(456 mg catechin)/
day or control (just 
followed) for 2 months
Blood glucose, HbA1c, insulin 
levels, and HOMA-IR did not differ 
from the control group
[61]
CRP, C-reactive protein; HbA1C, glycated hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; 
HOMA-IR, homeostasis model assessment of insulin resistance index; GLP-1, glucagon-like peptide 1; LDL-C,  
low-density lipoprotein cholesterol; TNF, tumor necrosis factor; T2D, type 2 diabetes; ↓, Reduction; ↑, increase.
Table 3. 
Studies that showed the effect of tea on insulin resistance and diabetes.
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